Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia

• Published in: Retina (Philadelphia, Pa.) Vol. 30; no. 3; p. 399
• Main Authors: Lalloum, Franck, Souied, Eric H, Bastuji-Garin, Sylvie, Puche, Nathalie, Querques, Giuseppe, Glacet-Bernard, Agnes, Coscas, Gabriel, Soubrane, Gisele, Leveziel, Nicolas
• Format: Journal Article
• Language: English
• Published: United States 01.03.2010
• Subjects: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Choroidal Neovascularization - diagnosis; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Coloring Agents; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Indocyanine Green; Injections; Male; Middle Aged; Myopia, Degenerative - complications; Prospective Studies; Ranibizumab; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitreous Body
• ISSN: 1539-2864
• DOI: 10.1097/iae.0b013e3181bcef24

The purpose of this study was to evaluate the efficacy of intravitreal injections of ranibizumab in choroidal neovascularization secondary to pathologic myopia. A prospective case series of 32 eyes of 32 patients affected with choroidal neovascularization secondary to pathologic myopia treated by intravitreal injections of ranibizumab. Best-corrected visual acuity, fundus examination, fluorescein angiography, indocyanine green angiography, and spectral domain-optical coherence tomography were performed for the diagnosis of myopic choroidal neovascularization. Best-corrected visual acuity and central retinal thickness measurement were performed monthly during the follow-up. The median number of injections was 3 with a median follow-up of 17 months. The median visual acuity at baseline was 20/100 and improved to 20/50 at final examination (P < 0.0001). Best-corrected visual acuity improved by > or = 3 lines in 15 of 32 eyes (46.8%). The median central thickness was 336 microm (range, 179-663 microm) at baseline and 233 microm (range, 125-465 microm) at final examination (P < 0.0001). No severe drug-related side effect was reported. In our series of myopic choroidal neovascularization, intravitreal injections of ranibizumab showed visual acuity improvement and retinal thickness reduction. Further prospective multicentric clinical trials are needed to evaluate the safety and the efficacy of this treatment.